Skip to main content
. 2009 Nov;1(3):183–205. doi: 10.1177/1758834009349119

Figure 4.

Figure
4.

Temsirolimus (blue line) versus temsirolimus and interferon-α (IFN, red line) versus IFN alone (black line) in first-line poor-risk renal cell cancer patients – overall survival [Hudes et al. 2007]. With permission, New England Medical Society.